Takeda Pharmaceutical (TAK) Revenue (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Revenue of $7.7 billion for Q2 2026, little changed year-over-year from $7.6 billion in Q2 2025, and down 1.61% quarter-over-quarter from $7.8 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Revenue (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Revenue history runs 10 years deep, the most recent figure standing at $7.7 billion for Q2 2026.
- In Q2 2026, Revenue changed 0.07% year-over-year to $7.7 billion; the TTM figure through Jun 2026 stood at $46.5 billion (up 0.74% YoY), while the FY2026 annual figure was $29.9 billion, changed 0.48% from the prior year.
- Revenue for Q2 2026 stood at $7.7 billion, down from $7.8 billion in the prior quarter.
- The five-year high for Revenue was $23.9 billion in Q3 2025, with the low at $6.9 billion in Q4 2024.
- The 5-year median for Revenue is $7.8 billion (2022), against an average of $10.3 billion.
- The sharpest annual moves came in 2022 and 2023: Revenue decreased 13.32% in 2022, then jumped 206.56% in 2023.
- Takeda Pharmaceutical's Revenue stood at $7.8 billion in 2022, then dropped by 8.4% to $7.1 billion in 2023, then slipped by 2.54% to $6.9 billion in 2024, then increased by 2.64% to $7.1 billion in 2025, then advanced by 7.62% to $7.7 billion in 2026.
- Business Quant data shows TAK's Revenue at $7.7 billion in Q2 2026, $7.8 billion in Q1 2026, and $7.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 106.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 1.37 Bn |
| 10 | HUTCHMED (China) | 10.92 Bn | 9.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.65 Bn |
| Mar 31, 2026 | 7.78 Bn |
| Dec 31, 2025 | 7.11 Bn |
| Sep 30, 2025 | 23.95 Bn |
| Jun 30, 2025 | 7.65 Bn |
| Mar 31, 2025 | 7.92 Bn |
| Dec 31, 2024 | 6.93 Bn |
| Sep 30, 2024 | 23.65 Bn |
| Jun 30, 2024 | 7.76 Bn |
| Mar 31, 2024 | 8.15 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Sep 30, 2023 | 22.25 Bn |
| Jun 30, 2023 | 7.72 Bn |
| Mar 31, 2023 | 8.00 Bn |
| Dec 31, 2022 | 7.76 Bn |
| Sep 30, 2022 | 7.26 Bn |
| Jun 30, 2022 | 7.52 Bn |
| Mar 31, 2022 | 8.37 Bn |
| Dec 31, 2021 | 7.93 Bn |
| Sep 30, 2021 | 7.67 Bn |